Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Achieve Life Sciences announced its Q1 2026 financial results, successfully closing a $354 million private placement to fund its Phase 3 trial and commercialization of cytisinicline, a potential first new FDA-approved therapy for smoking and vaping cessation in over 20 years. The company appointed Andrew D. Goldberg, MD as CEO, expanded its board, …